Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sofosbuvir - Gilead Sciences

Next Previous
X
Search
Drug Profile

Sofosbuvir - Gilead Sciences

Alternative Names: GS-7977; HEPCINAT; Hepcvir; P-7977; PSI-7977; Sovaldi; SoviHep

Latest Information Update: 06 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmasset
  • Developer Bristol-Myers Squibb; Gilead Sciences; Hannover Medical School
  • Class Antivirals; Phosphoric acid esters; Pyrimidine nucleotides; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C
  • Phase II Hepatitis E

Most Recent Events

  • 28 Dec 2022 No development reported - Phase-II for Hepatitis C (Combination therapy, In adolescents, In children, Treatment-naive, Treatment-experienced) in Australia (PO)
  • 28 Dec 2022 No development reported - Phase-II for Hepatitis C (Combination therapy, In adolescents, In children, Treatment-naive, Treatment-experienced) in Poland (PO)
  • 20 Apr 2021 Bristol-Myers Squibb terminates a phase II trial in Hepatitis C (Combination therapy, In adolescents, In children, Treatment-naive, Treatment-experienced) in Australia, Poland, Germany, Spain and Taiwan, due to change in business objectives (NCT03487848) (EudraCT2017-003338-94)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top